Loading Bonafide Research

Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market Outlook, 2030

Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap.

The Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) market has swiftly risen to prominence within the global pharmaceutical outsourcing sector, driven by a blend of cost benefits, advancing technical capabilities, and a flourishing pharmaceutical and biotechnology environment. As pharmaceutical firms persist in optimizing operations and minimizing internal manufacturing presence, Asia Pacific has established itself as an essential region providing scalable, high-quality, and cost-efficient CDMO services. With the increasing need for small molecule therapeutics in areas such as oncology, infectious diseases, and chronic conditions, the region’s CDMO market is experiencing strong growth and strategic investments. At the heart of this advancement is an increase in pharmaceutical R&D activities in key nations such as China, India, Japan, South Korea, and Australia. These nations have been making substantial investments in pharmaceutical infrastructure, technology transfer, regulatory compliance, and workforce training, which enables local CDMOs to fulfill international benchmarks. Furthermore, the increasing number of biotech startups and collaborations with academic research institutions is further enhancing demand for CDMO partnerships, particularly in early-stage development and clinical trial material production. CDMOs in Asia Pacific are progressively transitioning from being mere low-cost producers to comprehensive service suppliers providing full-spectrum solutions, including process development, API synthesis, formulation, clinical supply, and commercial manufacturing.

Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap of $234,210.0 million over 2022-2031. India and China are leading this shift, with India recognized for its strengths in active pharmaceutical ingredient (API) production and China becoming a frontrunner in both API and finished dosage formulation (FDF) manufacturing. Both countries have achieved considerable advancements in aligning with global regulatory standards established by the U. S. FDA, EMA, and WHO. Consequently, global pharmaceutical firms are increasingly turning to Asia Pacific not just for cost advantages but also for the region’s growing technical proficiency, quicker turnaround periods, and expanding innovation capabilities. Simultaneously, Japan and South Korea enhance the sector through advanced manufacturing technologies, quality assurance, and innovations in drug delivery systems, particularly in branded and specialty formulations. Among the most significant trends in the Asia Pacific CDMO market is the transition toward high-value, complex molecules such as highly potent APIs (HPAPIs), chiral compounds, and controlled substances. CDMOs are allocating resources to specialized containment facilities, digital manufacturing technologies, and continuous processing methods to address these requirements. Moreover, the emergence of personalized medicine, orphan drugs, and targeted therapies has spurred a demand for smaller, more adaptable batch sizes and rapid scale-up capabilities—an area in which many Asia Pacific CDMOs are achieving considerable progress.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The Asia Pacific Small Molecule CDMO market is mainly influenced by key pharmaceutical centers such as China, India, Japan, South Korea, and Australia, each making distinct contributions to the area's increasing importance in the global outsourcing arena. China is notable as a worldwide frontrunner in both Active Pharmaceutical Ingredients (API) and Finished Dosage Formulation (FDF) production. It gains advantages from extensive production capabilities, significant government backing, and improving adherence to international regulatory frameworks like the FDA and EMA. Chinese CDMOs are swiftly progressing into high-value offerings, including highly potent APIs and continuous manufacturing techniques. India, historically recognized as the "pharmacy of the world," plays a leading role in creating generic medications and complex APIs. Indian CDMOs possess extensive expertise in cost-efficient, high-volume production and have a robust export framework, delivering to markets throughout the U. S. , Europe, and Africa. India’s strong talent pool and favorable intellectual property climate keep attracting worldwide pharmaceutical collaborators. Japan adds value through its innovation-oriented pharmaceutical industry and rigorous regulatory quality, positioning it as an essential area for branded drug development and specialized formulations. Japanese CDMOs concentrate on high-end production and provide sophisticated drug delivery solutions, particularly for local and regional markets. South Korea is developing as a rising CDMO center with robust governmental support and an emphasis on biopharmaceuticals and cutting-edge manufacturing technologies. Korean CDMOs are channeling investments into both small molecule and biologics capabilities, aiding regional supply chain diversification. Australia, though smaller in scope, holds a crucial position in early-phase development, clinical trial manufacturing, and regulatory compliance assistance. It is a preferred location for biotech startups and global pharmaceutical firms executing Phase I and II trials because of its efficient regulatory system.

The Asia Pacific market for Small Molecule CDMO is divided into Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF). The API section consists of both Branded Drugs and Generic Drugs, with generic APIs occupying a larger market share owing to the region’s cost efficiencies and strong export focus. India and China are at the forefront of API production, backed by formidable manufacturing infrastructures and regulatory approvals. In contrast, the FDF segment, which includes Oral Solid Drugs, Injectable Drugs, Semi-solid or Liquid Drugs, and Other FDFs, is growing swiftly due to the rising demand for ready-to-administer forms. Oral solid drugs continue to be prevalent, but the injectable segment is gaining traction due to the increasing occurrence of chronic and lifestyle-related conditions. Investments in aseptic processing and formulation technologies are empowering regional CDMOs to meet both domestic and international market needs. The transition towards complex generics and specialty formulations is persistently propelling innovation and revenue growth in this sector. The Asia Pacific Small Molecule CDMO market is divided by service type into Preclinical Use, Clinical Use (Phases I–IV), and Commercial Use. Preclinical services, which comprise toxicology studies and formulation development, are gaining traction due to the rising volume of drug discovery initiatives. Clinical use services are proliferating through all four phases, with Phase I and II leading, especially in Australia and South Korea, because of streamlined regulatory frameworks and sophisticated clinical trial infrastructures. The burgeoning biotech ecosystem in the region further stimulates demand in these initial stages. Commercial Use services, which encompass large-scale production, packaging, and lifecycle management, are expanding quickly due to the surging number of drug approvals and the outsourcing of commercial manufacturing by pharmaceutical companies. As international clients pursue dependable and scalable production partners, Asia Pacific CDMOs are investing in GMP-compliant facilities and automation technologies to function as comprehensive providers from development through to commercialization.

The Asia Pacific Small Molecule CDMO market is classified by customer type into Pharmaceutical Firms and Biotechnology Firms. Pharmaceutical companies represent the predominant client base, depending on CDMOs for cost-efficient manufacturing of both branded and generic medications. These businesses are progressively outsourcing both API and FDF production to Asia Pacific partners to optimize operations and satisfy global demand. Simultaneously, biotechnology firms—often concentrating on innovation and early-stage drug development—rely on CDMOs for their expertise in scaling formulations and facilitating clinical trials. The rapid expansion of biotech hubs in China, India, South Korea, and Australia has intensified this trend. Startups and mid-sized biotechs, in particular, seek enduring CDMO collaborations to expedite timelines and lower capital expenses. The rising prevalence of biotech-driven treatments in oncology and personalized medicine is also prompting CDMOs to broaden their technical capabilities and provide more adaptable, end-to-end solutions tailored to the changing needs of both customer segments. The Asia Pacific Small Molecule CDMO market is varied across multiple therapeutic areas, with prominent segments such as Infectious Diseases, Oncology, and Cardiovascular Disorders. The Infectious Diseases segment gained traction during the COVID-19 pandemic and continues to fuel CDMO demand with the production of antiviral and antibacterial medications. Oncology is an important focus area due to the increasing incidence of cancer in the region and the worldwide demand for oncology pipelines, leading to investments in highly potent API facilities. Cardiovascular Disorders, Central Nervous System, and Metabolic Diseases also represent important segments due to the prevalence of lifestyle-related diseases. The Respiratory Disorders and Ophthalmology segments are experiencing incremental growth spurred by advancements in targeted therapies. As regulatory frameworks in Asia Pacific advance and market access enhances, CDMOs are broadening their capabilities to manage complex chemistries and specialty formulations across these therapeutic areas. This diversification fosters sustainable growth and maintains strategic relevance to global pharmaceutical pipelines.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO)Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Active Pharmaceutical Ingredients (API)
• Branded Drugs
• Generic Drugs
• Finished Dosage Formulations (FDF)
• Oral Solid Drugs
• Injectable Drugs
• Semi-solid or Liquid Drugs
• Other FDFs

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari


Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Preclinical Use
• Clinical Use
• Phase I
• Phase II
• Phase III
• Phase IV
• Commercial Use

By Customer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharmaceutical Firms
• Biotechnology Firms

By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Table of Contents

  • 1 Introduction 7
  • 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
  • 1.2 Research Methodology 11
  • 1.2.1 Overview of Market Research Methodology 11
  • 1.2.2 Market Assumption 12
  • 1.2.3 Secondary Data 12
  • 1.2.4 Primary Data 12
  • 1.2.5 Data Filtration and Model Design 13
  • 1.2.6 Market Size/Share Estimation 14
  • 1.2.7 Research Limitations 15
  • 1.3 Executive Summary 16
  • 2 Market Overview and Dynamics 19
  • 2.1 Market Size and Forecast 19
  • 2.1.1 Impact of COVID-19 on World Economy 20
  • 2.1.2 Impact of COVID-19 on the Market 22
  • 2.2 Major Growth Drivers 24
  • 2.3 Market Restraints and Challenges 28
  • 2.4 Emerging Opportunities and Market Trends 31
  • 2.5 Porter’s Fiver Forces Analysis 35
  • 3 Segmentation of Asia Pacific Market by Product Type 39
  • 3.1 Market Overview by Product Type 39
  • 3.2 Active Pharmaceutical Ingredients (API) 41
  • 3.2.1 Branded Drugs 42
  • 3.2.2 Generic Drugs 43
  • 3.3 Finished Dosage Formulations (FDF) 44
  • 3.3.1 Oral Solid Drugs 46
  • 3.3.2 Injectable Drugs 47
  • 3.3.3 Semi-solid or Liquid Drugs 48
  • 3.3.4 Other FDFs 49
  • 4 Segmentation of Asia Pacific Market by Service Type 50
  • 4.1 Market Overview by Service Type 50
  • 4.2 Preclinical Use 52
  • 4.3 Clinical Use 53
  • 4.3.1 Phase I 55
  • 4.3.2 Phase II 56
  • 4.3.3 Phase III 57
  • 4.3.4 Phase IV 58
  • 4.4 Commercial Use 59
  • 5 Segmentation of Asia Pacific Market by Customer Type 60
  • 5.1 Market Overview by Customer Type 60
  • 5.2 Pharmaceutical Firms 62
  • 5.3 Biotechnology Firms 63
  • 6 Segmentation of Asia Pacific Market by Therapeutic Area 64
  • 6.1 Market Overview by Therapeutic Area 64
  • 6.2 Infectious Diseases 66
  • 6.3 Oncology 67
  • 6.4 Ophthalmology 68
  • 6.5 Cardiovascular Disorders 69
  • 6.6 Central Nervous System 70
  • 6.7 Respiratory Disorders 71
  • 6.8 Metabolic Diseases 72
  • 6.9 Other Therapeutic Areas 73
  • 7 Asia-Pacific Market 2021-2031 by Country 74
  • 7.1 Overview of Asia-Pacific Market 74
  • 7.2 Japan 77
  • 7.3 China 80
  • 7.4 Australia 82
  • 7.5 India 84
  • 7.6 South Korea 86
  • 7.7 Rest of APAC Region 88
  • 8 Competitive Landscape 90
  • 8.1 Overview of Key Vendors 90
  • 8.2 New Product Launch, Partnership, Investment, and M&A 93
  • 8.3 Company Profiles 94
  • Boehringer Ingelheim 94
  • Cambrex Corporation 96
  • Catalent 97
  • Cipla 98
  • Covance Inc. 99
  • Lonza Group Ltd. 100
  • Medley Pharmaceuticals 101
  • NatcoPharma 102
  • Patheon (Thermo Fisher Scientific, Inc.) 103
  • Piramal Pharma Solutions 104
  • RedHillBiopharma 105
  • Siegfried Holding AG 106
  • STA Pharmaceutical 107
  • Sun Pharmaceutical 108
  • Teva 109
  • RELATED REPORTS 110

List of Tables:

Table 1. Snapshot of Asia Pacific Small Molecule CDMO Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. Worldwide Total Number of Registered Clinical Trials 27
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule CDMO Market 31
Table 5. Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 39
Table 6. Asia Pacific Small Molecule CDMO Market: API by Type, 2021-2031, $ mn 41
Table 7. Asia Pacific Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn 45
Table 8. Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 50
Table 9. Asia Pacific Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn 54
Table 10. Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn 60
Table 11. Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 64
Table 12. APAC Small Molecule CDMO Market by Country, 2021-2031, $ mn 75
Table 13. Japan Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 79
Table 14. Japan Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 79
Table 15. Japan Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 79
Table 16. China Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 81
Table 17. China Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 81
Table 18. China Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 81
Table 19. Australia Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 83
Table 20. Australia Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 83
Table 21. Australia Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 83
Table 22. India Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 85
Table 23. India Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 85
Table 24. India Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 85
Table 25. South Korea Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 87
Table 26. South Korea Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 87
Table 27. South Korea Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 87
Table 28. Small Molecule CDMO Market in Rest of APAC by Country/Region, 2021-2031, $ mn 89
Table 29. Boehringer Ingelheim: Company Snapshot 94
Table 30. Boehringer Ingelheim: Business Segmentation 95
Table 31. Boehringer Ingelheim: Product Portfolio 95

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Asia Pacific Small Molecule CDMO Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Small Molecule CDMO Market 24
Figure 7. Primary Restraints and Impact Factors of Asia Pacific Small Molecule CDMO Market 28
Figure 8. Investment Opportunity Analysis 32
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific Small Molecule CDMO Market 35
Figure 10. Breakdown of Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 40
Figure 11. Asia Pacific Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 40
Figure 12. Asia Pacific Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 41
Figure 13. Asia Pacific Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 42
Figure 14. Asia Pacific Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 43
Figure 15. Asia Pacific Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 44
Figure 16. Asia Pacific Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 46
Figure 17. Asia Pacific Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 47
Figure 18. Asia Pacific Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 48
Figure 19. Asia Pacific Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 49
Figure 20. Breakdown of Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 51
Figure 21. Asia Pacific Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 51
Figure 22. Asia Pacific Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 52
Figure 23. Asia Pacific Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 53
Figure 24. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 55
Figure 25. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 56
Figure 26. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 57
Figure 27. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 58
Figure 28. Asia Pacific Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 59
Figure 29. Breakdown of Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 61
Figure 30. Asia Pacific Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 61
Figure 31. Asia Pacific Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 62
Figure 32. Asia Pacific Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 63
Figure 33. Breakdown of Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 65
Figure 34. Asia Pacific Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 65
Figure 35. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 66
Figure 36. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 67
Figure 37. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 68
Figure 38. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 69
Figure 39. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 70
Figure 40. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 71
Figure 41. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 72
Figure 42. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 73
Figure 43. Breakdown of APAC Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 75
Figure 44. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 76
Figure 45. Small Molecule CDMO Market in Japan, 2021-2031, $ mn 78
Figure 46. Small Molecule CDMO Market in China, 2021-2031, $ mn 80
Figure 47. Small Molecule CDMO Market in Australia, 2021-2031, $ mn 82
Figure 48. Small Molecule CDMO Market in India, 2021-2031, $ mn 84
Figure 49. Small Molecule CDMO Market in South Korea, 2021-2031, $ mn 86
Figure 50. Small Molecule CDMO Market in Rest of APAC, 2021-2031, $ mn 88
Figure 51. Growth Stage of Asia Pacific Small Molecule CDMO Industry over the Forecast Period 90
Logo

Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market Outlook, 2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Claude Summarize

Contact usWe are friendly and approachable, give us a call.